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We report the encapsulation of highly hydrophobic 16-electron organometallic
ruthenium and osmium carborane complexes [Ru/Os(p-cymene)(1,2-dicarba-closo-
dodecarborane-1,2-dithiolate)] (1 and 2) in Pluronic® triblock copolymer P123 core–
shell micelles. The spherical nanoparticles RuMs and OsMs, dispersed in water, were
characterized by dynamic light scattering (DLS), cryogenic transmission electron
microscopy (cryo-TEM), and synchrotron small-angle X-ray scattering (SAXS; diameter
ca. 15 and 19 nm, respectively). Complexes 1 and 2 were highly active towards A2780
human ovarian cancer cells (IC50 0.17 and 2.50 mM, respectively) and the encapsulated
complexes, as RuMs and OsMs nanoparticles, were less potent (IC50 6.69 mM and 117.5
mM, respectively), but more selective towards cancer cells compared to normal cells.1 Introduction
Dicarba-closo-dodecarboranes are a class of boron-rich compounds with globular
structures and diameters of ca. 1 nm (diameter of a rotating phenyl) that possess
unusual properties, including high symmetry and remarkable stability.1 These
characteristics have given rise to numerous applications, and carboranes have
been used as building blocks in various systems, such as dendrimers,2 polymers3
and nanoparticles.4,5 They also have been extensively studied as potential boron
neutron capture (BNCT) therapeutic agents,6,7 and as bioisosters of phenyl groups
and pharmacophores for targeted drug development.8 Nevertheless, selective and
eﬀective delivery of boron agents is still a key issue that hinders their further
clinical development.9On the other hand, half-sandwich complexes of rutheniumaDepartment of Chemistry, University of Warwick, Gibbet Hill Road, Coventry CV4 7AL, UK. E-mail: N.Barry@
warwick.ac.uk; P.J.Sadler@warwick.ac.uk
bSchool of Life Sciences, University of Warwick, Gibbet Hill Road, Coventry CV4 7AL, UK
cAustralian Synchrotron, 800 Blackburn Road, Clayton, Victoria 3168, Australia
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View Article Onlineand osmium are a versatile class of organometallic compounds. Their biological
properties have raised considerable expectations for their use in the treatment of
cancer since the early 2000s, and they are considered a promising alternative to
platinum-based chemotherapeutics.10,11 We have recently discussed how the
combination of arene ruthenium(II)/osmium(II) complexes and carboranes has
unexplored potential in medicine.12 Furthermore, such complexes exhibit
unusual chemistry: coordination of the bulky, electron-decient carborane ligand
1,2-dicarba-closo-dodecarborane-1,2-dithiolato to an arene-Ru or Os metal centre
leads to the isolation of rare stable 16-electron complexes, such as [Ru/Os(p-
cymene)(1,2-dicarba-closo-dodecarborane-1,2-dithiolate)] (1 and 2). However,
these complexes are highly hydrophobic, and their biological applications are
impaired by the lack of solubility in water. We have recently discussed how
nanotechnology may help to overcome such challenges in medicinal inorganic
chemistry.13Here, we report the encapsulation of these hydrophobic complexes in
water-soluble polymer micelles.
The class of ABA triblock copolymers, where A ¼ hydrophilic block poly-
(ethylene oxide) (PEO) and B ¼ hydrophobic block poly(propylene oxide) (PPO),
are commercially available as Pluronic® (non-proprietary name “poloxamers”)
and oﬀer a pool of more than 50 amphiphilic,14 water-soluble and polymorphic
materials. The physical and chemical properties of Pluronic® copolymers can be
nely tuned by modifying the molar mass ratio between the PEO and PPO blocks
(from 1 : 9 to 8 : 2), which directly modies their in vivo properties and interac-
tions with cells and cell membranes, thus providing high potential for the design
of innovative nanomedicines and new biomaterials.15 To exploit the chemistry of
carborane-containing arene ruthenium complexes in aqueous solution, and to
take advantage of their unique properties, we have encapsulated the 16-electron
complexes 1 and 2 in Pluronic® triblock copolymer P123 micelles (Fig. 1). The
resulting polymeric micelles RuMs and OsMs, dispersed in water, have been
characterized by UV-visible spectroscopy, DLS, cryo-TEM, and SAXS studies.
Complexes 1 and 2 andmicelles RuMs andOsMs were tested against the A2780
human ovarian cancer cell line. The ruthenium-based complex and micelles were
also tested against MRC5 broblasts, as an example of non-cancerous, but fast
dividing, cells to determine their selectivity and potential therapeutic window.
Such a nanotechnology-based strategy not only allows the utilisation of preciousFig. 1 Self-assembly formation of RuMs and OsMs (the red dots in 1 and 2 are boron–
hydrogen vertices).
230 | Faraday Discuss., 2014, 175, 229–240 This journal is © The Royal Society of Chemistry 2014
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View Article Onlinemetal complexes containing carborane ligands in aqueous solution, but also
oﬀers the possibility of formulating and delivering a large number of these
complexes (ca. 60 per particle) to cancer cells, thus generating a high intracellular
boron concentration (ca. 600 per particle). There is currently much interest in the
therapeutic use of boron-based pharmaceuticals, owing to their chemico-bio-
logical properties, to expand potential medical applications in prevention, diag-
nosis and therapy.162 Characterisation of the micellar formulations
RuMs and OsMs
The organometallic half-sandwich RuII and OsII arene complexes [Ru/Os(p-
cymene)(1,2-dicarba-closo-dodecarborane-1,2-dithiolate)] (1/2) were synthesized
as previously reported.17 These complexes have a pseudo-octahedral structure,
with a p-bonded arene occupying 3 coordination sites, a S-bound chelated
dithiolato dicarba-closo-dodecarborane ligand, and a vacant 6th site (Fig. 1). They
are 16-electron complexes and therefore electron-decient at the metal.18
Complexes 1 and 2 are highly hydrophobic and insoluble in water.8 To achieve
dispersion in water,13 we encapsulated 1 and 2 in the water-soluble amphiphilic
triblock copolymer P123 (poly(ethylene glycol)-block-poly(propylene glycol)-block-
poly(ethylene glycol)) (PEO-PPO-PEO), by mixing a tetrahydrofuran (THF) solution
of 1 or 2 with an aqueous solution of polymer P123 (THF–H2O: 1/10 v/v; [complex]
¼ 5 mg mL1), at ambient temperature for 4 h (Fig. 1). The encapsulation of the
metal complexes in P123 micelles (P123Ms) was accompanied by a dramatic
colour change from transparent to blue and purple for RuMs and OsMs,
respectively, indicative of the presence of the 16-electron complexes 1 and 2 in the
micelles. We have recently reported the full characterisation of OsMs micelles,19
and now present the characterisation of micellar formulation RuMs, in compar-
ison with previous data obtained on OsMs micelles.
Dynamic light scattering (DLS) experiments (Fig. 2) unambiguously demon-
strated that polymer P123 and complex 1 and 2 self-assemble in aqueous solution.
Encapsulation decreased the micellar size (hydrodynamic diameter) of P123 fromFig. 2 DLS spectra of P123Ms, RuMs, and OsMs (1 mg mL1, H2O).
This journal is © The Royal Society of Chemistry 2014 Faraday Discuss., 2014, 175, 229–240 | 231
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View Article Online19.6  1.8 nm to 11.9  4.1 nm for RuMs and 11.5  2.3 nm for OsMs with
dispersities (Đ) of 0.04 and 0.03, respectively. Although micellar size usually
increases aer encapsulation of organic molecules, incorporation of hydrophobic
molecules can result in expulsion of water from micelles, causing a contraction.20
The hydrophobicity of 1 and 2 probably results in a stronger folding of the PPO
chains around the complexes through hydrophobic interactions, with concomi-
tant expulsion of water from the core. A small-in-number (<0.01% in number)
second population of RuMs and OsMs particles is found at Dh  220 nm, which
exhibits a strong intensity in DLS and is due to aggregation of some particles.
Cryo-TEM analysis without staining was performed on Quantifoil® carbon-
coated grids, in order to observe the morphology of the nanoparticles in solution.
The high contrast provided by the presence of the heavy ruthenium and osmium
centres allowed facile imaging without staining (Fig. 3). From these analyses, it
was clear that spherical micellar morphologies are formed when polymer P123
encapsulates complexes 1 or 2. The observed diameters of these nano-spheres are
10.45 3.43 nm for RuMs and 7.85 1.97 nm for OsMs with very low dispersities
(<1.12). These data are in accordance with the hydrodynamic diameters deter-
mined by DLS, within experimental error.
To gain further insight into their structures in aqueous solution, and to
conrm cryo-TEM and DLS results, RuMs, OsMs and P123Ms were analyzed by
SAXS (Fig. 4). The experimental proles were tted using IgorPro soware21 to
three model functions for spherical micelles: SphereForm,22 CoreShellSphere,22
and PolyCoreShellRatio23 (PCR). The PCR model tted excellently for all micelles
with very low dispersity parameters (0.124 for RuMs, 0.161 for OsMs and 0.146 for
P123Ms, 0 being an ideal mono-disperse system, Table 1). These analyses
demonstrated that RuMs and OsMs self-assembly leads to core–shell micelles
with a core diameter of 9.88  0.25 nm and 9.06  0.12 nm, and a shell diameter
of 9.09  0.29 nm and 6.50  0.15 nm, respectively (Table 1). The diameters ofFig. 3 Cryo-TEM of the self-assembled block copolymer micelles containing encapsu-
lated ruthenium and osmium carborane complexes. (A) and (B) are images and (C) and (D)
are particle counting/histogram analyses for RuMs and OsMs, respectively.
232 | Faraday Discuss., 2014, 175, 229–240 This journal is © The Royal Society of Chemistry 2014
Fig. 4 Small-angle X-ray scattering (SAXS) experimental proﬁles and ﬁtting with the
PolyCoreShellRatio model of micelles (A) P123Ms, (B) RuMs, (C)OsMs: 1 mgmL1 aqueous
solutions.
Table 1 Physical characteristics of RuMs and P123Ms micelles determined by DLS, cryo-
TEM and SAXS at 1 mg mL1
Parameter
Micelles
RuMs OsMsa P123Ms
Aggregation number 66  4 52  6 20  2
Ru/Os complexes per micelle 59  14 52  11 0
DLS diameter (nm) 11.9  4.1 11.5  2.3 19.6  1.8
DLS dispersity 0.04 0.03 0.03
Cryo-TEM diameter (nm) 10.45  3.43 7.85  1.97 ndb
Cryo-TEM dispersity 1.11 1.06 ndb
SAXS total diameter (nm) 18.97  0.54 15.56  0.27 18.96  0.23
SAXS core diameter (nm) 9.88  0.25 9.06  0.12 6.74  0.06
SAXS shell diameter (nm) 9.09  0.29 6.50  0.15 12.22  0.17
SAXS dispersity 0.124 0.161 0.146
a Data from ref. 19. b Not determined.
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View Article OnlineRuMs and OsMs micelles determined by DLS and cryo-TEM are in accordance
with the core diameter determined by SAXS within experimental error. From these
data (scattering length density calculations, degrees of polymerization of
Pluronic® P123, and the molecular formulae of the polymer and of complex 1/2),
aggregation numbers for RuMs, OsMs and P123Ms micelles were determined as
20  2 monomer chains per P123Ms micelle, 66  4 monomer chains per RuMs
micelles and 52  6 monomer chains per OsMs micelles. Determinations of
ruthenium and osmium by inductively coupled plasma mass spectrometry (ICP-
MS) gave a polymer/complex 1 ratio of 1/0.9  0.11 for RuMs and 1/1  0.09 for
OsMs showing that the 66 polymer chains self-assembled with 59  14 complexes
1 in RuMs and 52 monomer chains self-assembled with 52  11 complexes 2 (see
Table 1).3 Anticancer activity of complexes 1 and 2 and
micellar formulations RuMs and OsMs
Synthetic polymer therapeutics are of particular interest in medicine, due to their
synthetic versatility, as well as their tunable properties.24 A number of biologicallyThis journal is © The Royal Society of Chemistry 2014 Faraday Discuss., 2014, 175, 229–240 | 233
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View Article Onlineactive polymer–drug conjugates and polymeric formulations, such as micelles,
hydrogels and polymer-coated nanoparticles, are currently in clinical develop-
ment.25 Among the most commonly used polymers for applications in medicine
are the ABA Pluronic® triblock block copolymers, which are particularly suitable
for the design of bio-inspired, bioengineered and biomimetic polymer nano-
particles. The utilisation of Pluronic® block copolymers as drug delivery
systems,26–31 biological response modiers,32–36 pharmaceutical ingredients,27,37,38
and steric stabilizers to lyotropic liquid crystalline particles39–41 has led to recent
clinical advances.15
Inorganic compounds oﬀer diﬀerent mechanisms of drug action depending
on the metal used, their structures and their redox properties.11,42–85 They can this
be utilized for the design of novel drugs in the treatment of a broad range of
diseases,86 and their combination with nanotechnology tools, such as polymer
nanoparticles, may provide opportunities for tackling medical challenges in
the near future.13 Surprisingly, only a few studies have been devoted to the
encapsulation of inorganic compounds (mainly cisplatin) in Pluronic® block
copolymer-based nanostructures.87,88
We studied the antiproliferative activity of complexes 1, 2 and micelles RuMs
and OsMs in A2780 human ovarian cancer cells (Table 2). Cells were exposed for
24 h to the complexes (dissolved in 5% dimethyl sulfoxide (DMSO)/95% saline
and further diluted in cell culture medium until working concentrations in the
range of 100–0.01 mMwere achieved with amaximumDMSO concentration of 1%)
or micelles (100% saline, further diluted with cell culture medium to a range of
concentration 200–0.10 mM). Aer this, drugs were removed and cells were
washed and placed in fresh growthmedium for a further 72 h as a recovery period.
Cell viability was then assessed using the sulforhodamine B (SRB) colorimetric
assay. Complex 1 is highly potent (IC50 170 nM), about 7 more potent than the
clinical drug cisplatin. Complex 1 is also 39 more potent than RuMs micelles,
which still exhibit good (micromolar) activity towards cancer cells and are as
potent as the clinical drug carboplatin. Interestingly, RuMsmicelles are 4more
selective than 1, showing only moderate toxicity towards MRC5-broblast cells.
Finally, the formulation of complexes 1 and 2 in polymer micelles has allowed
dispersal of hydrophobic ruthenium and osmium arene complexes in water in aTable 2 IC50 values (mM) of complexes 1 and 2 and micelles P123Ms, RuMs and OsMs
towards A2780 human ovarian cancer cells, IC50 values (mM) of complex 1 and micelles
RuMs for MRC5-ﬁbroblast cells, and selectivity factors (IC50(MRC5)/IC50(A2780))
Compound
IC50 (mM)
A2780 MRC5-broblast Selectivity factor
P123Ms >100 nd —
1 0.17  0.02 0.31  0.03 1.82
2 2.50  0.09 nd —
RuMs 6.69  0.33 51.6  0.9 7.71
OsMs 117.50  0.18 nd —
Cisplatin 1.20  0.10 9.5 (ref. 89) 7.92
Carboplatin 6.0  0.7 (ref. 90) nd —
234 | Faraday Discuss., 2014, 175, 229–240 This journal is © The Royal Society of Chemistry 2014
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View Article Onlinemanner suitable for administration to cancer cells (administration to cancer cells
in water, without the need to add DMSO).
4 Conclusion
We have encapsulated highly hydrophobic carborane-containing precious metal
complexes in triblock copolymer micelles. This has allowed dispersal of hydro-
phobic ruthenium and osmium arene complexes in water in amanner suitable for
administration to cancer cells. Although entrapment of the 16-electron complexes
1 and 2 in Pluronic® micelles leads to a reduction in their anticancer potency, the
micelles exhibit enhanced selectivity towards cancer cells compared to normal
cells. Polymer encapsulation of metal carborane complexes also provides the
potential for delivering high amounts of boron to cells, which is of interest for
boron neutron capture therapy (BNCT). The neutron capture ability of such
micelles is currently under investigation.
5 Experimental section
Materials
The preparation of the complexes [Ru/Os(p-cym)(1,2-dicarba-closo-dodecaborane-
1,2-dithiolato)] (1 and 2) was based on a previous report.17 The preparation of the
OsMs micelles was based on a previous report.19 The triblock copolymer P123
[poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol)] was
purchased from Sigma-Aldrich and used as received. Anhydrous tetrahydrofuran
(Aldrich) was used. 18.2 mega-ohm purity water was collected from a Purelab®
UHQ USF Elga system. Holey carbon grids with 200 mesh and lacey carbon grids
were purchased from Quantifoil Micro Tools Gmbh and Elektron Technology UK
Ltd, respectively, and used as received.
Synthesis of RuMs
A tetrahydrofuran (THF) solution (1 mL) of complex 1 (5 mg mL1) was added to
an aqueous solution (10 mL) of polymer P123 (5 mg mL1) and the resultant
mixture was stirred at ambient temperature for 4 h. The solution was then dia-
lyzed to remove the THF (MWCO ¼ 1000 Da), for 48 h, and then freeze-dried to
give RuMs. A similar procedure was used for synthesizing OsMs with 1 mol equiv.
of the Os analogue and 1 mol equiv. of polymer P123.
Instrumentation
UV-visible spectroscopy. UV-visible absorption spectra were recorded on a
temperature-controlled Varian CARY 300 Biospectrophotometer using 1 cm path-
length quartz cuvettes (0.5 mL).
Inductively coupled plasma mass spectrometry (ICP-MS). Osmium or ruthe-
nium content was determined using an ICP-MS Agilent technologies 7500 series
instrument. The standard for osmium was purchased from Aldrich. Calibration
curves were prepared using Ru/Os standard solutions in double deionised water
(ddw) with 3% nitric acid, ranging between 50 and 0.5 ppb (9 points). Samples
were freshly prepared in ddw with 3% nitric acid. Readings were made in no-gas
mode with a detection limit of 1 ppt.This journal is © The Royal Society of Chemistry 2014 Faraday Discuss., 2014, 175, 229–240 | 235
Faraday Discussions Paper
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 0
1 
O
ct
ob
er
 2
01
4.
 D
ow
nl
oa
de
d 
on
 1
/8
/2
01
9 
4:
39
:2
3 
PM
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article OnlineDynamic light scattering (DLS). The hydrodynamic diameter (Dh) of nano-
particles was determined by DLS. Typically, an aqueous nanoparticle solution was
measured with a Malvern Zetasizer NanoS instrument equipped with a 4 mWHe–
Ne 633 nm laser module at 25 C. Measurements were carried out at a detector
angle of 173 (back scattering). Data were analyzed by the Malvern DTS 6.20
soware. Dh was calculated by tting the apparent diﬀusion coeﬃcient in the
Stokes–Einstein equation Dh ¼ kT/(3phDapp), where k is the Boltzmann constant,
T is the temperature and h is the viscosity of the solvent. Dh coincides with the
hydrodynamic diameter when the sample is made of monodispersed spherical
particles (Dapp equals the translational diﬀusion Dt).
Cryogenic electron microscopy (cryo-TEM). A JEOL 2010F TEM was operated at
200 keV and images were recorded on a Gatan UltraScan 4000 camera for cryo-
TEM and glow discharge. The samples were prepared at ambient temperature by
placing a droplet on a TEM grid. The extra liquid was then blotted with a lter
paper and the grid was inserted into liquid ethane at its freezing point. The frozen
samples were subsequently kept under liquid nitrogen.
Small-angle X-ray scattering (SAXS). Measurements were carried out on the
SAXS beamline at the Australian Synchrotron facility at a photon energy of 11 keV.
The samples in solution were in 1.5 mm diameter quartz capillaries. The
measurements were collected at a sample to detector distance of 3.252 m to give a
q range of 0.004 to 0.2 A˚1, where q is the scattering vector and is related to the
scattering angle (q) and the photon wavelength (l) by the following eqn (1):
q ¼ 4p sinðqÞ
l
(1)
The scattering from a blank (H2O) was measured in the same location as
sample collection and was subtracted for each measurement. Data were
normalized for total transmitted ux using a quantitative beamstop detector and
absolute scaled using water as an absolute intensity standard. The two-dimen-
sional SAXS images were converted in one-dimensional SAXS proles (I(q) versus
q) by circular averaging, where I(q) is the scattering intensity. Functions were used
from the NCNR package. Scattering length densities were calculated using the
“Scattering Length Density Calculator” provided by NIST Center for Neutron
Research.
Cell culture. A2780 human ovarian carcinoma and MRC5 human fetal lung
broblasts were obtained from the European Collection of Cell Cultures (ECACC).
Both cell lines were grown in Roswell Park Memorial Institute medium (RPMI-
1640) supplemented with 10% of fetal calf serum, 1% of 2 mM glutamine and 1%
penicillin/streptomycin. All cells were grown as adherent monolayers at 310 K in a
5% CO2 humidied atmosphere and passaged at approximately 70–80%
conuency.
In vitro growth inhibition assay. Briey, 96-well plates were used to seed 5000
cells per well. The plates were le to pre-incubate in drug-free media at 310 K for
48 h before adding diﬀerent concentrations of the compounds to be tested. A drug
exposure period of 24 h was allowed. Aer this, supernatants were removed by
suction and each well was washed with PBS. A further 48 h was allowed for the
cells to recover in drug-free medium at 310 K. The SRB assay was used to deter-
mine cell viability. IC50 values, as the concentration which caused 50% of cell236 | Faraday Discuss., 2014, 175, 229–240 This journal is © The Royal Society of Chemistry 2014
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View Article Onlinedeath, were determined as duplicates of triplicates in two independent sets of
experiments and their standard deviations were calculated.Acknowledgements
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